John Dixon, MD
Internal Medicine · Saraland, ALNPI 1316040413
Payments from drug & device makers
Across 126 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$246
- Novartis$217
- AbbVie$213
- Pfizer$117
- Lilly USA, LLC$81
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$77
- plus $837 from 25 others
What the payments were for
- Food & beverage$1,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $246 |
| Novartis | 13 | $217 |
| AbbVie(2 entities) | 21 | $213 |
| Pfizer | 9 | $117 |
| Lilly USA, LLC | 6 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| Astellas Pharma US Inc | 5 | $75 |
| AstraZeneca | 5 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Ironwood Pharmaceuticals, Inc | 4 | $66 |
| Amarin Pharma, Inc. | 4 | $57 |
| Novo Nordisk | 4 | $56 |
| Boehringer Ingelheim | 3 | $40 |
| Amgen | 3 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| GSK | 2 | $28 |
| Boston Scientific | 2 | $28 |
| Merck | 2 | $26 |
| Bayer | 2 | $25 |
| Abbott | 1 | $24 |
| Nevro Corp. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$1,787 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 109 | $416,255 |
| EliquisApixaban | 794 | $316,609 |
| JanuviaSitagliptin Phosphate | 404 | $225,972 |
| MounjaroTirzepatide | 177 | $191,341 |
| OzempicSemaglutide | 122 | $134,235 |
| JardianceEmpagliflozin | 198 | $111,967 |
| XareltoRivaroxaban | 230 | $93,616 |
| LinzessLinaclotide | 151 | $92,986 |
| TrulicityDulaglutide | 92 | $80,248 |
| XifaxanRifaximin | 32 | $51,356 |
| AustedoDeutetrabenazine | 34 | $50,644 |
| TradjentaLinagliptin | 175 | $50,271 |
| RexultiBrexpiprazole | 63 | $43,773 |
| FarxigaDapagliflozin Propanediol | 98 | $40,982 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $38,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $117 | $333,596848 claims |
| Lilly USA, LLCMounjaro, Trulicity | $81 | $271,589269 claims |
| MerckJanuvia, Isentress | $26 | $246,927415 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $40 | $186,036416 claims |
| Novo NordiskOzempic | $56 | $134,235122 claims |
| AbbVieLinzess, Restasis | $213 | $109,282175 claims |
| Johnson & JohnsonXarelto | $246 | $93,616230 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $28 | $64,119116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $77 | $51,35632 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $15 | $50,64434 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $67 | $43,77363 claims |
| AstraZenecaFarxiga | $68 | $40,98298 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Saraland
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.